E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women

Background: Preservation of E-cadherin expression is usually related to non-invasive and well differentiated breast carcinomas. Purpose: The aim of this study was to evaluate E-cadherin immunohistochemical expression in estrogen receptor (ER) positive and negative infiltrating ductal breast carcinomas. Methods: Twenty-three postmenopausal patients with Stage II, operable, infiltrating ductal breast carcinomas were divided into groups A (ER+; n = 13) and B (ER-; n = 10). E-cadherin immunohistochemical expression was assessed semiquantitatively according to membrane staining intensity and classified as negative (p< 10% of cells with stained mem-branes), positive + (10-50% of cells stained) or positive ++ (p> 50% of cells stained). Fisher’s exact test was used to compare the dis-tribution of staining intensity in the two groups (p < 0.05). Results: In group A (ER+), E-cadherin staining was positive in all cases: + (n = 3; 23%) and ++ (n = 10; 77%) compared to three cases (30%) in group B (ER-), + (n = 2; 20%) and ++ (n = 1; 10%). This difference was statistically significant (p < 0.0005). Conclusions: The present results indicate that E-cadherin expression loss is signifi-cantly associated with ER-negative tumors and therefore with a more aggressive phenotype of invasive ductal breast carcinoma.

Breast; Cancer; E-cadherin; Estrogen receptor; Cell adhesion molecules.

[1] Cowin P., Rowlands T.M., Hatsell S.J.: “Cadherins and catenins in breast cancer”. Curr Opin. Cell. Biol., 2005, 17, 499.

[2] Boussadia O., Kutsch S., Hierholzer A., Delmas V., Kemler R.: “E-cadherin is a survival factor for the lactating mouse mammary gland”. Mech. Dev., 2002, 115, 53.

[3] Takeichi M.: “Cadherin cell adhesion receptors as a morphogenetic regulator”. Science, 1991, 251, 1451.

[4] Nelson W.J.: “Regulation of cell-cell adhesion by the cadherin-catenin complex”. Biochem. Soc. Trans., 2008, 36, 149.

[5] Takeichi M.: “Morphogenetic roles of classic cadherins”. Curr. Opin. Cell. Biol., 1995, 7, 619.

[6] Gumbiner B.M.: “Cell adhesion: the molecular basis of tissue architecture and morphogenesis”. Cell, 1996, 84, 345.

[7] Rowlands T.M., Symonds J.M., Farookhi R., Blaschuk O.W.: “Cadherins: crucial regulators of structure and function in reproductive tissues”. Rev. Reprod., 2000, 5, 53.

[8] Qureshi H.S., Linden M.D., Divine G., Raju U.B.: “E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters”. Am. J. Clin. Pathol., 2006, 125, 377.

[9] Gamallo C., Palacios J., Suarez A., Pizarro A., Navarro P., Quintanilla M. et al.: “Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma”. Am. J. Pathol., 1993, 142, 987.

[10] Guriec N., Marcellin L., Gairard B., Caldéroli H., Wilk A., Renaud R. et al.: “E-cadherin mRNA expression in breast carcinomas cor-relates with overall and disease-free survival”. Invasion Metastasis, 1996, 16, 19.

[11] Cleton-Jansen A.M.: “E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?”. Breast Cancer Res. 2002, 4, 5.

[12] Berx G., Van Roy F.: “The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression”. Breast Cancer Res., 2001, 3, 289.

[13] Blanco M.J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J. et al.: “Correlation of Snail expression with histological grade and lymph node status in breast carcinomas”. Oncogene, 2002, 21, 3241.

[14] Tan P.H., Bay B.H., Yip G., Selvarajan S., Tan P., Wu J. et al.: “Immunohistochemical detection of Ki67 in breast cancer corre-lates with transcriptional regulation of genes related to apoptosis and cell death”. Mod. Pathol., 2005, 18, 374.

[15] Kuroda H., Tamaru J., Takeuchi I., Ohnisi K., Sakamoto G., Adachi A. et al.: “Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of breast”. Virchows Arch., 2006, 448, 500.

[16] Agresti A.: Categorical Data Analysis, second edition, New York, John Wiley and Sons, 2002.

[17] Jothy S., Munro S.B., LeDuy L., McClure D., Blaschuk O.W.: “Adhesion or anti-adhesion in cancer: what matters more?”. Cancer Metastasis Rev., 1995, 14, 363.

[18] Oka H., Shiozaki H., Kobayashi K., Inoue M., Tahara H., Kobayashi T., et al. Expression of E-cadherin cell adhesion mole-cules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993, 53, 1696.

[19] Siitonen S.M., Kononen J.T., Helin H.J., Rantala I.S., Holli K.A., Isola J.J. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am. J. Clin. Pathol. 1996, 105, 394.

[20] Moll R., Mitze M., Frixen U.H., Birchmeier W. Differential loss of

E- cadherin expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol. 1993,143, 1731.

[21] Hunt N.C., Douglas-Jones A.G., Jasani B., Morgan J.M., Pignatelli

M. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch. 1997, 430, 285.

[22] Lipponen P., Saarelainen E., Ji H., Aaltomaa S., Syrjänen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J. Pathol. 1994, 174, 101.

[23] Acs G., Lawton T.J., Rebbeck T.R., LiVolsi V.A., Zhang P.J. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol. 2001, 115, 85.

[24] Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 2000, 124, 966.

[25] Dowsett M., Archer C., Assersohn L., Gregory R.K., Ellis P.A., Salter J. Clinical studies of apoptosis and proliferation in breast cancer. Endocr. Relat. Cancer 1999, 6, 25.

[26] da Silva B.B., Pires C.G., dos Santos A.R., de Castro-Leão A.H., Alencar A.P., Lopes-Costa P.V. Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer. Gynecol. Obstet. Invest. 2009, 67, 103.

[27] da Silva B.B., da Silva Júnior R.G., Borges U.S., da Silveira Filho M. A., Pimentel I.C., Gebrim L.H., et al. Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J. Surg. Oncol. 2005, 90, 77.

[28] Millen E.C., da Silva B.B., Gebrim L.H. Apoptotic index in breast carcinoma cells following tamoxifen treatment. Int. J. Gynaecol. Obstet. 2006, 95, 64.

[29] dos Santos L.G., Lopes-Costa P.V., dos Santos A.R., Facina G., da Silva B.B. Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma. Eur. J. Gynaecol. Oncol. 2008, 29, 459.

[30] Fujita N., Jayne D.L., Kajita M., Geigerman C., Moreno C.S., Wade P.A. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113, 207.

[31] Rakha E.A., El-Sayed M., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25.

[32] Mahler-Araujo B., Savage K., Parry S., Reis-Filho J.S. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J. Clin. Pathol. 2008, 61, 615.